NVAF
- Another retrospective analysis of US Veterans Affairs data in patients with severe obesity (weight >120 mg) indicated that NOACs (apixaban, dabigatran, and rivaroxaban) were as effective as warfarin in reducing the risk of stroke; and were associated with lower bleeding and hemorrhagic stroke rates compared with warfarin
Briasoulis (Cardiovasc Drugs Ther 2021)
Comparative effectiveness and safety of DOACs in
obese patients with AF
Comparative effectiveness and safety of DOACs in
obese patients with AF
- A single-center, retrospective study suggested that apixaban and rivaroxaban may be safe and effective at preventing thromboembolic events, with no increased risk of bleeding in patients with AF. Patients with BMI ≥50 kg/m2 compared to patients with BMI <30 kg/m2
O'Kane CP (Pharmacotherapy 2022)
Apixaban and rivaroxaban use for atrial fibrillation in
patients with obesity and BMI ≥50 kg/m2
Apixaban and rivaroxaban use for atrial fibrillation in
patients with obesity and BMI ≥50 kg/m2
